Last updated 13 days ago
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
7140 patients around the world
Available in Argentina, Mexico, Brazil
Eli Lilly and Company
106Research sites
7140Patients around the world
This study is for people with
Cardiovascular disease
Renal disease
Chronic kidney disease
Requirements for the patient
From 50 Years
All Gender
Medical requirements
- Have established ASCVD and/or CKD.
- Have type 1 diabetes.Have had a major heart condition within 60 days prior to screening.Have New York Heart Association Functional Classification Class IV heart failure.
Sites
CER Instituto Médico - Quilmes, Buenos Aires
CEDIMBA - DIM Clínica Privada - Buenos Aires
Instituto de Investigaciones Clínicas Córdoba
Instituto Médico de la Fundación Estudios Clínicos - Rosario
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Instituto Médico Damic S.R.L.
Instituto de Especialidades de la Salud Rosario Clínica del Tórax
Sociedad de Beneficencia Hospital Italiano - Córdoba
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Médica - Rosario, Santa Fe
Centro de Investigaciones Clínicas - IESR - Rosario, Santa Fe
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Cardiovascular diseaseChronic kidney disease
Requirements
From 50 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07241390
